As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing its work to improve awareness of and education around the rare disease.

Secondary efficacy endpoints include duration of response (DoR), disease control rate (DCR), clinical benefit rate, progression-free survival (PFS), time to response ...

A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising ...

Our study found that doing these kinds of screenings on patients doesn't make any marked difference in their long-term survival rates." J. Brent Muhlestein, principal investigator of the study and ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell ...

The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, ...

In 2016, cancer biologist Johanna Joyce of the Memorial Sloan Kettering Cancer Center published a study in Science that ...

The primary endpoint was progression free survival (PFS), and the secondary endpoints included overall survival, objective ...

Here are 10 lifesaving precautions and preparations to follow—regardless of location—to survive unexpected situations when ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...